Fig. 3

Sensitization of AML LSCs, but not HSCs, to BIX-01294-induced apoptosis via PERK inhibition. a, Flow cytometric analysis, based on annexin-V/7-AAD exclusion, of apoptotic fractions after treatment of CD34⁺-enriched primary AML cells from 16 cases with BIX-01294 (5 μmol/L) in the absence or presence of GSK2606414 (10 μmol/L) for 48 h. Left panel: annexin-V⁺ 7-AAD⁺ CD34⁺ cells; right panel: CD34⁺CD38⁻ primary LSCs. b, Flow cytometric analysis, based on annexin-V/7-AAD exclusion, of apoptotic fractions after treatment of normal HSCs from five donors with BIX-01294 (5 μmol/L) in the absence or presence of GSK2606414 (10 μmol/L) for 48 h. Left panel: annexin-V⁺ 7-AAD⁺ CD34⁺ cells; right panel: CD34⁺CD38⁻ primary HSCs. c, Representative scatter plot of CD34⁺-enriched primary AML cells